UBS raises Booz Allen Hamilton stock price target on backlog growth By Investing.com
UBS raised its price target for Booz Allen Hamilton (NYSE:BAH) to $78 from $70 and kept a Neutral rating. It cited fiscal 2027 Q1 funded backlog up 15% year over year and a 1.5x book-to-bill ratio. UBS noted bookings support the high end of revenue guidance, but obligations data and Civil guidance point to a weaker back half.
How this was made
The 30-second read
Why it matters
The key tradable element is the PT raise to $78 from $70, justified by funded backlog up 15% YoY and a 1.5x book-to-bill, tempered by concerns that current obligations data does not fully back the back-half weighted guidance and that Civil guidance implies a large sequential decline.
Market read
A fresh sell-side PT update tied to backlog momentum can move expectations, but the Neutral rating and guidance-timing concerns suggest limited conviction.
What to watch
Investors may discount the backlog strength if near-term segment guidance deteriorates, and the article’s mention of “green shoots” is not the same as confirmed leading indicators of growth.
Background
UBS updated its view on Booz Allen Hamilton after fiscal 2027 Q1 results, focusing on funded backlog growth and bookings strength.
Ticker impact
UBS raised Booz Allen Hamilton’s price target to $78 from $70 and cited funded backlog up 15% YoY in fiscal 2027 Q1.
Near-term upside bias versus prior PT, but expect volatility if investors focus on the sequential Civil guidance decline and the mismatch between backlog data and back-half weighted guidance.
The article provides a concrete PT change plus specific backlog metrics (15% YoY funded backlog, 1.5x book-to-bill) while also noting UBS concerns about guidance support and a large sequential decline in Civil.
Market effects
Supports the defense IT/services narrative that backlog conversion and funded bookings are stabilizing, but highlights execution risk around segment guidance timing.
Limited, as the catalyst is company-specific analyst research rather than a macro or regional shock.
Low; the news is primarily a US-listed single-name valuation update.
Counterpoint
The PT increase may not translate into sustained upside because UBS explicitly says obligations data does not yet support the heavily back-half weighted guidance and flags a large sequential Civil decline.
Key entities
- companyBooz Allen Hamilton
UBS raised its price target to $78 from $70 while maintaining a Neutral rating, citing funded backlog growth and bookings strength.
- analyst_firmUBS
Issued the price-target change and provided the backlog and guidance interpretation summarized in the article.
